Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma
- PMID: 36108656
- DOI: 10.1016/S0140-6736(22)01749-4
Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma
Conflict of interest statement
PS received a research grant from Pierre Fabre, fees unrelated to this manuscript from Bristol-Myers Squibb, MSD, Merck-Serono, Pfizer, Roche-Genentech, Pierre Fabre, and Novartis. PS received non-financial support from Bristol-Myers Squibb, MSD, Roche-Genentech, Pierre Fabre, and Novartis. AB received personal fees unrelated to this manuscript from Sanofi and Merck-Serono. These competing interests were all related to other skin cancers than Merkel cell carcinoma, apart from the personal fees from Merck-Serono, which were related to Merkel cell carcinoma.
Comment on
-
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.Lancet. 2022 Sep 24;400(10357):1008-1019. doi: 10.1016/S0140-6736(22)01659-2. Epub 2022 Sep 12. Lancet. 2022. PMID: 36108657 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
